ym 529 has been researched along with Prostatic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, H; Matsuda, T; Sugi, M; Taniguchi, H; Yanishi, M; Yoshida, T | 1 |
| Keller, ET; Miwa, S; Mizokami, A; Namiki, M; Taichman, R; Zhang, J | 1 |
| Ashimine, S; Hatano, T; Horiguchi, Y; Maeda, H; Ochiai, A; Ogawa, Y; Tachibana, M; Yonou, H; Yoshioka, K | 1 |
1 trial(s) available for ym 529 and Prostatic Neoplasms
| Article | Year |
|---|---|
A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (
Topics: Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Humans; Imidazoles; Injections, Subcutaneous; Male; Prostatic Neoplasms | 2020 |
2 other study(ies) available for ym 529 and Prostatic Neoplasms
| Article | Year |
|---|---|
The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Topics: Animals; Bone Marrow; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chemokine CXCL12; Chemokines, CXC; Diphosphonates; Humans; Imidazoles; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Osteoblasts; Prostatic Neoplasms; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2005 |
The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Topics: Animals; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Osteoblasts; Prostatic Neoplasms; Transplantation, Heterologous | 2007 |